Sanofi SA's Fiscal Year is From January To December - All Figures are in EUR, Billions.
The item "Operating-Expenses" stands at 24.50 Billion Euros for the trailing twelve months (TTM) period ending 09/30/2025.
Sanofi SA's third quarter result of 6.14 Billion EUR for the item "Operating Expenses" represents a decrease of -2.14 percent compared to it's second quarter result.
Also, Sanofi SA's third quarter result of 6.14 Billion EUR for the item "Operating Expenses" represents a decrease of -4.69 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Sanofi SA's third quarter result of 24.50 Billion EUR for the item "Operating Expenses" represents a decrease of -1.22 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 19.53 percent compared to the value the year prior.
The 1 year change in percent is 19.53.
The 3 year change in percent is 6.99.
The 5 year change in percent is 88.42.
The 10 year change in percent is 49.22.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Operating Expenses | 905,699,262,464.00 |
![]() | Johnson & Johnson - Operating Expenses | 486,508,953,600.00 |
![]() | AbbVie Inc - Operating Expenses | 399,570,305,024.00 |
![]() | Roche Holding AG - Operating Expenses | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Operating Expenses | 280,205,508,085.11 |